MX2020007772A - Anticuerpos humanos contra hemaglutinina de influenza. - Google Patents
Anticuerpos humanos contra hemaglutinina de influenza.Info
- Publication number
- MX2020007772A MX2020007772A MX2020007772A MX2020007772A MX2020007772A MX 2020007772 A MX2020007772 A MX 2020007772A MX 2020007772 A MX2020007772 A MX 2020007772A MX 2020007772 A MX2020007772 A MX 2020007772A MX 2020007772 A MX2020007772 A MX 2020007772A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- influenza
- influenza hemagglutinin
- human antibodies
- bind
- Prior art date
Links
- 101710154606 Hemagglutinin Proteins 0.000 title abstract 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 title abstract 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 title abstract 4
- 101710176177 Protein A56 Proteins 0.000 title abstract 4
- 239000000185 hemagglutinin Substances 0.000 title abstract 4
- 206010022000 influenza Diseases 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000007501 viral attachment Effects 0.000 abstract 1
- 230000008478 viral entry into host cell Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona anticuerpos monoclonales, o fragmentos de unión al antígeno de estos, que se unen a la proteína hemaglutinina (HA) de influenza, composiciones farmacéuticas que comprenden los anticuerpos y métodos de uso. Los anticuerpos de la invención son útiles para inhibir o neutralizar la actividad del virus de influenza, y proporcionan así un medio para tratar o prevenir la infección por influenza en seres humanos. En algunas modalidades, la invención proporciona el uso de uno o más anticuerpos que se unen a la HA de influenza para prevenir el acoplamiento viral y/o la entrada en células huésped. Los anticuerpos de la invención pueden usarse profilácticamente o terapéuticamente y pueden usarse solos o en combinación con uno o más de otros agentes o vacunas antivirales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622480P | 2018-01-26 | 2018-01-26 | |
| PCT/US2019/015029 WO2019147867A1 (en) | 2018-01-26 | 2019-01-24 | Human antibodies to influenza hemagglutinin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020007772A true MX2020007772A (es) | 2020-09-18 |
Family
ID=66286952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020007772A MX2020007772A (es) | 2018-01-26 | 2019-01-24 | Anticuerpos humanos contra hemaglutinina de influenza. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US11780907B2 (es) |
| EP (1) | EP3743442A1 (es) |
| JP (2) | JP7372925B2 (es) |
| KR (1) | KR20200115517A (es) |
| CN (1) | CN111670195A (es) |
| AU (1) | AU2019212480A1 (es) |
| BR (1) | BR112020014849A2 (es) |
| CA (1) | CA3088194A1 (es) |
| CL (1) | CL2020001884A1 (es) |
| CO (1) | CO2020009043A2 (es) |
| EA (1) | EA202091563A1 (es) |
| IL (1) | IL275884B1 (es) |
| MA (1) | MA51681A (es) |
| MX (1) | MX2020007772A (es) |
| PH (1) | PH12020551051A1 (es) |
| SG (1) | SG11202006379UA (es) |
| WO (1) | WO2019147867A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023519930A (ja) * | 2020-04-01 | 2023-05-15 | ユニバーシティ オブ ロチェスター | インフルエンザｈ３ｎ２ウイルスのヘマグルチニン（ｈａ）およびノイラミニダーゼ（ｎａ）に対するモノクローナル抗体 |
| CA3197537A1 (en) * | 2020-11-23 | 2022-05-27 | Davide Corti | Antibodies against influenza a viruses |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| AU2006247425A1 (en) * | 2005-05-16 | 2006-11-23 | Morphotek, Inc. | Regulated vectors for selection of cells exhibiting desired phenotypes |
| CN102585002A (zh) | 2006-06-02 | 2012-07-18 | 瑞泽恩制药公司 | 人il-6受体的高亲和力抗体 |
| MY170607A (en) | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| EP1947423A1 (en) | 2007-01-16 | 2008-07-23 | Sony Deutschland Gmbh | Distance, orientation and velocity sensitive controller |
| EP2155787A4 (en) | 2007-05-11 | 2010-06-16 | Temasek Life Sciences Lab Ltd | SPECIFIC TO THE H5-SUBTYPE BINDING PROTEINS SUITED TO THE DIAGNOSIS AND MONITORING OF THE H5 BIRGRAP |
| JP5490695B2 (ja) | 2007-09-13 | 2014-05-14 | テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド | インフルエンザウイルスｈ５亜型からのヘマグルチニンに特異的なモノクローナル抗体およびそれらの使用 |
| JP5490696B2 (ja) | 2007-09-13 | 2014-05-14 | テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド | インフルエンザウイルスｈ５亜型またはｎ１亜型からのヘマグルチニンおよびノイラミニダーゼに特異的なモノクローナル抗体ならびにそれらの使用 |
| EP2222701B1 (en) | 2007-12-06 | 2017-11-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
| EP2250197B1 (en) | 2008-02-05 | 2016-05-11 | Temasek Life Sciences Laboratory Limited | Binding protein and epitope-blocking elisa for the universal detection of h5-subtype influenza viruses |
| WO2009121004A2 (en) | 2008-03-28 | 2009-10-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to viral antigens |
| JP2011528902A (ja) | 2008-07-25 | 2011-12-01 | インスティテュート・フォー・リサーチ・イン・バイオメディシン | 抗ａ型インフルエンザウイルス中和抗体およびその使用 |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| EP2328928A2 (en) | 2008-08-25 | 2011-06-08 | Dana-Farber Cancer Institute, Inc. | Conserved influenza hemagglutinin epitope and antibodies thereto |
| AU2008365616A1 (en) | 2008-12-24 | 2011-08-11 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof |
| CN102264896B (zh) * | 2008-12-25 | 2014-02-26 | 国立大学法人大阪大学 | 抗人流感病毒人型抗体 |
| BRPI1012749B1 (pt) | 2009-05-11 | 2022-01-11 | Janssen Vaccines & Prevention B.V. | Anticorpo monoclonal humano, seu uso e seu método de produção, imunoconjugado, e composição farmacêutica |
| AU2010249046A1 (en) | 2009-05-13 | 2011-12-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to influenza viruses |
| EP2445936A1 (en) | 2009-06-26 | 2012-05-02 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
| PT2505654T (pt) | 2010-02-08 | 2016-11-18 | Regeneron Pharma | Rato de cadeia leve comum |
| WO2011111966A2 (en) | 2010-03-08 | 2011-09-15 | Celltrion, Inc. | Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses |
| WO2011160083A1 (en) | 2010-06-17 | 2011-12-22 | Trellis Bioscience, Inc. | Antibodies useful in passive influenza immuization |
| US9534042B2 (en) | 2010-09-03 | 2017-01-03 | Fujita Health University | Influenza virus-neutralizing antibody and screening method therefor |
| US20130289246A1 (en) | 2010-09-30 | 2013-10-31 | Vanderbilt University | Influenza virus antibodies and immunogens and uses therefor |
| MX346206B (es) | 2011-07-14 | 2017-03-09 | Crucell Holland Bv | Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. |
| ITRM20110606A1 (it) | 2011-11-16 | 2013-05-17 | Ist Superiore Sanita | Peptidi della lattoferrina per lo uso come inibitori ad ampio spettro dellainfezione da virus della influenza. |
| KR20140112495A (ko) | 2011-12-02 | 2014-09-23 | 에임 쎄라퓨틱스 비.브이. | 인플루엔자 a 바이러스 특이적 항체 |
| CA2861515A1 (en) | 2011-12-05 | 2013-06-13 | Trellis Bioscience, Llc | Antibodies useful in passive influenza immunization |
| WO2013132007A1 (en) | 2012-03-08 | 2013-09-12 | Crucell Holland B.V. | Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| MX2015005860A (es) * | 2012-11-13 | 2015-08-10 | Genentech Inc | Anticuerpos de antihemaglutinina y metodo de uso. |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| KR20140118682A (ko) | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| DK3052192T3 (da) | 2013-10-02 | 2020-09-28 | Medimmune Llc | Neutraliserende anti-influenza a-antistoffer og anvendelser deraf |
| EP3102598A2 (en) * | 2014-02-04 | 2016-12-14 | Contrafect Corporation | Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof |
| BR112016022113A2 (pt) | 2014-03-27 | 2017-10-31 | Genentech Inc | anticorpos anti-hemaglutinina do vírus influenza b e métodos de uso |
| CN104031118B (zh) | 2014-06-19 | 2016-04-13 | 天津大学 | 鼠多瘤病毒衣壳粒的新型亲和肽配基及其设计筛选方法 |
| TWI702229B (zh) * | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| US10435462B2 (en) | 2015-03-31 | 2019-10-08 | Viro Dynamics Corporation | Hybrid influenza seed viruses, compositions thereof, and use thereof in the diagnosis or therapy of influenza |
| EP3280730B1 (en) | 2015-04-08 | 2024-01-03 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
| AU2016271323B2 (en) | 2015-06-01 | 2022-08-25 | Medimmune, Llc | Neutralizing anti-influenza binding molecules and uses thereof |
| WO2017192589A1 (en) | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| WO2020221450A1 (en) | 2019-04-30 | 2020-11-05 | Humabs Biomed Sa | Antibodies and methods for treatment of influenza a infection |
-
2019
- 2019-01-24 WO PCT/US2019/015029 patent/WO2019147867A1/en unknown
- 2019-01-24 MA MA051681A patent/MA51681A/fr unknown
- 2019-01-24 CN CN201980009873.XA patent/CN111670195A/zh active Pending
- 2019-01-24 US US16/964,579 patent/US11780907B2/en active Active
- 2019-01-24 AU AU2019212480A patent/AU2019212480A1/en active Pending
- 2019-01-24 CA CA3088194A patent/CA3088194A1/en active Pending
- 2019-01-24 EA EA202091563A patent/EA202091563A1/ru unknown
- 2019-01-24 JP JP2020539709A patent/JP7372925B2/ja active Active
- 2019-01-24 MX MX2020007772A patent/MX2020007772A/es unknown
- 2019-01-24 SG SG11202006379UA patent/SG11202006379UA/en unknown
- 2019-01-24 BR BR112020014849-0A patent/BR112020014849A2/pt unknown
- 2019-01-24 EP EP19719656.1A patent/EP3743442A1/en active Pending
- 2019-01-24 KR KR1020207022064A patent/KR20200115517A/ko active Search and Examination
-
2020
- 2020-07-06 IL IL275884A patent/IL275884B1/en unknown
- 2020-07-07 PH PH12020551051A patent/PH12020551051A1/en unknown
- 2020-07-17 CL CL2020001884A patent/CL2020001884A1/es unknown
- 2020-07-23 CO CONC2020/0009043A patent/CO2020009043A2/es unknown
-
2023
- 2023-02-28 JP JP2023030129A patent/JP2023060018A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3743442A1 (en) | 2020-12-02 |
| SG11202006379UA (en) | 2020-07-29 |
| CL2020001884A1 (es) | 2020-12-11 |
| JP2023060018A (ja) | 2023-04-27 |
| JP2021511043A (ja) | 2021-05-06 |
| US20210371505A1 (en) | 2021-12-02 |
| MA51681A (fr) | 2021-05-05 |
| BR112020014849A2 (pt) | 2020-12-08 |
| IL275884B1 (en) | 2024-07-01 |
| KR20200115517A (ko) | 2020-10-07 |
| PH12020551051A1 (en) | 2021-08-23 |
| CN111670195A (zh) | 2020-09-15 |
| CA3088194A1 (en) | 2019-08-01 |
| US11780907B2 (en) | 2023-10-10 |
| WO2019147867A1 (en) | 2019-08-01 |
| IL275884A (en) | 2020-08-31 |
| WO2019147867A9 (en) | 2019-11-07 |
| AU2019212480A1 (en) | 2020-09-10 |
| CO2020009043A2 (es) | 2020-07-31 |
| JP7372925B2 (ja) | 2023-11-01 |
| EA202091563A1 (ru) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007679A (es) | Anticuerpos humanos para hemaglutinina de influenza. | |
| PH12018502673A1 (en) | Anti-zika virus antibodies and methods of use | |
| MX2021015687A (es) | Anticuerpos humanos contra glicoproteina del virus ebola. | |
| WO2020106358A8 (en) | Novel anti-zika virus antibodies and uses thereof | |
| BR112018072681A2 (pt) | anticorpos anti-il-1r3 humanizados | |
| PH12020551051A1 (en) | Human antibodies to influenza hemagglutinin | |
| EA201990988A1 (ru) | Антитела против chikv и пути их применения | |
| MX2021004356A (es) | Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas. | |
| MY184269A (en) | Broad-spectrum anti-influenza virus therapeutic peptides | |
| MX2015012399A (es) | Conjugado de peptidos inmunogenicos y metodo para inducir una respuesta a un anticuerpo terapeutico anti-influenza con los mismos. | |
| MX2017014343A (es) | Compuestos peptidomimeticos que neutralizan el virus influenza. | |
| EA201990300A1 (ru) | Антитела к вирусу зика и способы их применения | |
| EA202191973A2 (ru) | Человеческие антитела к гликопротеину вируса эбола | |
| CO2022005281A2 (es) | Anticuerpos antihemaglutinina y métodos de uso de estos | |
| ECSP21039816A (es) | Anticuerpos monoclonales antirrábicos y cóctel de estos | |
| MA40375A1 (fr) | Anticorps humains contre l'hémagglutinine de la grippe | |
| JOP20180058A1 (ar) | أجسام مضادة محيدة لفيروس نقص المناعة البشرية |